Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of $5.71, $0.47 worse than the analyst estimate of $6.18. Revenue for the quarter came in at $1.02 billion versus the consensus estimate of $1.11 billion.

GUIDANCE:

Jazz Pharmaceuticals sees FY2026 revenue of $4.600-4.750 billion, versus the consensus of $4.512 billion.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.